- Home
- PMAX vs GOVX Comparison
PMAX vs GOVX Comparison
Compare PMAX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- GOVX
- Stock Information
- Founded
- PMAX 2019
- GOVX 2001
- Country
- PMAX Hong Kong
- GOVX United States
- Employees
- PMAX N/A
- GOVX N/A
- Industry
- PMAX
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- GOVX Health Care
- Exchange
- PMAX Nasdaq
- GOVX Nasdaq
- Market Cap
- PMAX 7.9M
- GOVX 7.6M
- IPO Year
- PMAX 2024
- GOVX N/A
- Fundamental
- Price
- PMAX $0.37
- GOVX $0.75
- Analyst Decision
- PMAX
- GOVX Strong Buy
- Analyst Count
- PMAX 0
- GOVX 4
- Target Price
- PMAX N/A
- GOVX $10.50
- AVG Volume (30 Days)
- PMAX 2.0M
- GOVX 2.7M
- Earning Date
- PMAX 04-28-2025
- GOVX 08-05-2025
- Dividend Yield
- PMAX N/A
- GOVX N/A
- EPS Growth
- PMAX N/A
- GOVX N/A
- EPS
- PMAX N/A
- GOVX N/A
- Revenue
- PMAX $4,694,079.00
- GOVX $5,591,576.00
- Revenue This Year
- PMAX N/A
- GOVX N/A
- Revenue Next Year
- PMAX N/A
- GOVX N/A
- P/E Ratio
- PMAX N/A
- GOVX N/A
- Revenue Growth
- PMAX N/A
- GOVX N/A
- 52 Week Low
- PMAX $0.28
- GOVX $0.43
- 52 Week High
- PMAX $4.70
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- GOVX 47.67
- Support Level
- PMAX N/A
- GOVX $0.60
- Resistance Level
- PMAX N/A
- GOVX $0.76
- Average True Range (ATR)
- PMAX 0.00
- GOVX 0.08
- MACD
- PMAX 0.00
- GOVX 0.02
- Stochastic Oscillator
- PMAX 0.00
- GOVX 59.45
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.